Incyte Corporation (NASDAQ:INCY) – Stock analysts at Gabelli reduced their FY2021 earnings per share estimates for shares of Incyte Corporation in a report issued on Wednesday. Gabelli analyst J. He now anticipates that the biopharmaceutical company will post earnings per share of $5.00 for the year, down from their prior estimate of $5.20.

Several other research analysts also recently commented on the company. Oppenheimer Holdings, Inc. set a $135.00 price objective on Incyte Corporation and gave the stock a “hold” rating in a research note on Tuesday. BMO Capital Markets raised their price objective on Incyte Corporation from $162.00 to $166.00 and gave the stock an “outperform” rating in a research note on Tuesday. J P Morgan Chase & Co reaffirmed a “buy” rating on shares of Incyte Corporation in a research note on Tuesday. Goldman Sachs Group, Inc. (The) began coverage on Incyte Corporation in a research note on Friday, October 6th. They issued a “buy” rating and a $160.00 price objective on the stock. Finally, Jefferies Group LLC reaffirmed a “buy” rating on shares of Incyte Corporation in a research note on Friday, October 6th. Seven equities research analysts have rated the stock with a hold rating, eighteen have given a buy rating and one has given a strong buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $144.98.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Watch List News and is the property of of Watch List News. If you are reading this piece of content on another publication, it was copied illegally and reposted in violation of US and international copyright & trademark law. The original version of this piece of content can be read at https://www.watchlistnews.com/gabelli-equities-analysts-lower-earnings-estimates-for-incyte-corporation-incy/1678415.html.

Incyte Corporation (NASDAQ INCY) traded down $1.43 during midday trading on Thursday, hitting $105.08. The stock had a trading volume of 1,850,000 shares, compared to its average volume of 1,860,000. The company has a debt-to-equity ratio of 0.01, a quick ratio of 2.87 and a current ratio of 4.82. Incyte Corporation has a 1 year low of $83.01 and a 1 year high of $153.15.

Incyte Corporation (NASDAQ:INCY) last posted its quarterly earnings data on Tuesday, October 31st. The biopharmaceutical company reported $0.17 EPS for the quarter, topping the consensus estimate of $0.06 by $0.11. Incyte Corporation had a negative return on equity of 12.91% and a negative net margin of 10.90%. The firm had revenue of $381.50 million for the quarter, compared to the consensus estimate of $360.34 million. During the same quarter last year, the company earned $0.19 earnings per share. The business’s revenue for the quarter was up 41.6% compared to the same quarter last year.

In other news, President Herve Hoppenot sold 70,502 shares of Incyte Corporation stock in a transaction that occurred on Monday, September 18th. The stock was sold at an average price of $119.45, for a total value of $8,421,463.90. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider David W. Gryska sold 3,915 shares of Incyte Corporation stock in a transaction that occurred on Thursday, November 2nd. The stock was sold at an average price of $105.63, for a total value of $413,541.45. The disclosure for this sale can be found here. In the last quarter, insiders sold 102,062 shares of company stock valued at $12,652,893. Company insiders own 17.70% of the company’s stock.

Several institutional investors have recently made changes to their positions in INCY. D. Scott Neal Inc. purchased a new position in shares of Incyte Corporation in the 2nd quarter worth approximately $103,000. Cornerstone Advisors Inc. boosted its holdings in shares of Incyte Corporation by 19.6% in the 2nd quarter. Cornerstone Advisors Inc. now owns 884 shares of the biopharmaceutical company’s stock worth $111,000 after purchasing an additional 145 shares during the period. Tower Research Capital LLC TRC boosted its holdings in shares of Incyte Corporation by 13.8% in the 2nd quarter. Tower Research Capital LLC TRC now owns 891 shares of the biopharmaceutical company’s stock worth $112,000 after purchasing an additional 108 shares during the period. Exane Asset Management purchased a new position in shares of Incyte Corporation in the 2nd quarter worth approximately $126,000. Finally, Seven Eight Capital LP purchased a new position in shares of Incyte Corporation in the 2nd quarter worth approximately $129,000. Hedge funds and other institutional investors own 88.85% of the company’s stock.

Incyte Corporation Company Profile

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of therapeutics. Its portfolio includes compounds in various stages, ranging from preclinical to late-stage development, and commercialized products, such as JAKAFI (ruxolitinib) and ICLUSIG (ponatinib).

Earnings History and Estimates for Incyte Corporation (NASDAQ:INCY)

Receive News & Ratings for Incyte Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Incyte Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.